耐火性がんの痛みに対する低用量ナルトレクソン:初期安全性と有効性のケースシリーズ
Aila Malik1, Alice Ye2, Matthew Chung2
1Department of Physical Medicine and Rehabilitation, University of Texas Health Science Center at Houston, Houston, United States.
Journal of pain and symptom management
|August 23, 2025
まとめ
低用量ナルトレキソン (LDN) は,耐性がんの痛みの管理に有望であり,早期フォローアップで良好な耐受性と低有害事象の発生を示しています. この研究は,持続的な痛みを経験するがん患者にとって LDN が有益な選択肢であることを示唆しています.
科学分野:
- 腫瘍学
- 痛みの管理
- 薬理学について
背景:
- 低用量ナルトレキソン (LDN) は,非がん性慢性疼痛の非処方薬として使用されます.
- がんに関連する痛みに対する有効性は十分に確立されていません.
研究 の 目的:
- 耐火性がんの痛みに対するLDN療法の安全性と有効性を評価する.
- 開始から2回のフォローアップ訪問までの LDN の結果を評価する.
主な方法:
- LDNを処方されたがん患者 (2022年−2023年) の遡及的チャートレビュー.
- 患者の自己報告による痛みの改善により,反応した患者として分類された.
- がん診断,痛みタイプ,LDN用量,反応率,有害事象に関するデータ
主要な成果:
- 20人のがん患者はLDNを受け,45%が乳がんでした.
- 第1回と第2回フォローアップではそれぞれ80%と76. 9%の陽性反応率でした.
- 治療に関連した神経症は71%の応答率を示し,軽微な有害事象はまれで管理可能であった.
結論:
- LDNは,耐火性がんの痛みに対する潜在的な利点を提供しているようです.
- LDNは耐受性があり,この患者群では有害事象の発生率が低い.
- 癌の痛み管理のためのLDNのさらなる調査は正当化されています.
関連する概念動画
Analgesia and Pain Management
788
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
788
Opioid Analgesics: Synthetic and Semisynthetic Opioids
426
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
426
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
366
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
366
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


